

# Five-Year Results of a Prospective Multicenter Trial: AdVance™ XP for Postprostatectomy Incontinence in Patients with Favorable Prognostic Factors

Mumm JN et al. *Urol Int.* 2021;105(5-6):421-7.



## Objective of the study

Assess the security, value and efficacy of the second-generation AdVance XP Male Sling.

## Patient Selection\*

Patients excluded from the AdVance XP Sling study (who may be candidates for the AMS 800™ Artificial Urinary Sphincter):

- Earlier incontinence surgery
- Nocturnal urinary incontinence
- Former radiotherapy
- Functional urethra < 1cm during re-positioning test
- Poor external sphincter contractility
- More than 8 pads per day
- Previous history of urge incontinence

\* These are the exclusion criteria for this study, these are not the exclusion criteria for the device itself.



## 115 consecutive patients included



Follow-up at 3, 6, 12, 24, 36, 48 and 60 months.


## Definitions

- **Cure:** 0 pads in 24h or a maximum of 5g in the 24-h pad test.
- **Improvement:** ≥50% reduction in the 24-h pad test.
- **Failures:** < 50% reduction in the 24-h pad test.



Study results on next page →

## Long-term Efficacy



## Complications

**Intraoperative complications:** none

**Infections:** none

**Erosions:** none

**Pain:** "no participant was in need of pain relief therapy in the prolonged post-op phase for over 4 weeks"

**De-novo urge incontinence**  
(Clavien -Dindo IIa): 4.3%

**Urinary Tract Infection**  
(Clavien-Dindo IIb): 0.9%

**Single sling arm dissection**  
(Clavien-Dindo IIIb): 7.8%

**3 patients received post AdVance XP Sling irradiation. For 2 of these, incontinence symptoms returned.**

	Mean 24-hr pad test (grams)	ICIQ, mean	IQOL
Baseline (N=115)	272.0	14.9	67.3
24 months (N=114)	19.0	4.8	97.0
48 months (N=85)	33.8	5.3	96.9
60 months (N=59*)	18.3	5.0	96.8

\* N=59 (24 patients lost to follow-up, 2 patients deceased, 30 patients have not reached 60-month endpoint/other)

## Conclusion

**"The AdVance XP displays excellent continence results and secure effectiveness over a 5-year period. Moreover, these data are demonstrating low complication rates and improved quality of life in the long-term use of AdVance XP."**

### Earlier articles on this study

Bauer RM, Grabbert MT, Klehr B, et al. **36-month** data for the AdVance XP male sling: results of a prospective multicentre study. *BJU Int.* 2017 Apr;119(4):626-30.

Bauer RM, Gozzi C, Klehr B, et al. AdVance XP male sling: **2-year** results of a multicenter study. *World J Urol.* 2016 Jul;34(7):1025-30.

Grabbert M, Mumm JN, Klehr B, et al. Extended follow-up of the AdVance XP male sling in the treatment of male urinary stress incontinence after **48 months**: Results of a prospective and multicenter study. *Neurourol Urodyn.* 2019 Sep;38(7):1973-8.



[Link to full article: Five-Year Results of a Prospective Multicenter Trial: AdVance XP for Postprostatectomy-Incontinence in Patients with Favorable Prognostic Factors \(karger.com\)](https://www.karger.com/Link/doi/10.1159/000500000)

**Boston Scientific**  
Advancing science for life™

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.

Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, and potential adverse events.

The AdVance™ XP Male Sling System is intended for the placement of a suburethral sling for the treatment of male stress urinary incontinence (SUI). These devices are contraindicated for patients with urinary tract infections, blood coagulation disorders, a compromised immune system or any other condition that would compromise healing, with renal insufficiency, and upper urinary tract relative obstruction. Possible adverse events include, but are not limited to, urinary retention, return to incontinence and pain. MH-557013-AA

All trademarks are the property of their respective owners.

Boston Scientific Corporation  
300 Boston Scientific Way  
Marlborough, MA 01752  
www.bostonscientific.com

© 2021 Boston Scientific Corporation or its affiliates. All rights reserved.

MH-1025504-AA JUN 2021